Clinical use of topoisomerase I inhibitors in anticancer treatment

Medical and Pediatric Oncology

Volumn 35, Issue 4, 2000, Pages 385-402

  Rodriguez Galindo, Carlos ^a,b   Radomski, Kristine ^a,b   Stewart, Clinton F ^a,b   Furman, Wayne ^a,b   Santana, Victor M ^a,b   Houghton, Peter J ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Children; Irinotecan; Topoisomerase I inhibitors; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CELL CYCLE S PHASE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; REVIEW;

ADULT; ANIMAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHILD; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMAN; MICE; NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TOPOTECAN;

EID: 0033800708     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-911X(20001001)35:4<385::AID-MPO1>3.0.CO;2-E     Document Type: Review

References (202)

1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
2. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer
3. Treatment of malignant melanoma with camptothecin (MSC-100880)
4. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
5. The mechanisms of DNA topoisomerases
6. Camptothecins: From bench research to hospital wards
7. Induction of p53-dependent and p53-independent cellular responses by topoisomerase I inhibitors
8. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues
9. High-performance liquid chromatographic analysis of the new antitumour drug SK and F 104864-A (NSC 609699) in plasma
10. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
11. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
12. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
13. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors
14. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
15. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
16. Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN-38
17. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates
18. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
19. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
20. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
21. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin] by human hepatic microsomes
22. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
23. Phase I and pharmacokinetic trial of weekly CPT-11
24. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning
25. Identification of mutations at DNA topoisomerase I responsible for camtothecin resistance
26. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants
27. Reduced cellular accumulation of topotecan: A novel mechanism of resistance in a human ovarian cancer cell line
28. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein
29. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines
30. Schedule dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens
31. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells
32. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma
33. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines
34. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10(4-[1-piperidino]-1-piperidino)carboxyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomehtyl-10-hydroxycamptothecin
35. Tumor cell lines resistant to camptothecin analogues or other topo I inhibitors
36. Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast
37. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells
38. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models
39. Esterase comparison in neuroblastoma cells of human and rodent origin
40. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11
41. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors
42. CPT-11 in human coloncancer cell lines and xenografts: Characterization of cellular sensitivity determinants
43. Evaluation of 9-dimethylaminomethyl-10-hydrocamptothecin against xenografts derived from adult and childhood solid tumors
44. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low doses in protracted schedules to mice bearing xenografts of human tumors
45. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma
46. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays
47. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts
48. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts
49. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts
50. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents
51. Review of phase I clinical studies with topotecan
52. An overview of the clinical pharmacology of topotecan
53. Phase I study of topotecan for pediatric patients with malignant solid tumors
54. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia
55. Phase I and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group study
56. Pharmacokinetically guided dose adjustment reduces variability in topotecan (TPT) systemic exposure in children with solid tumors
57. Pharmacokinetically-guided use of topotecan (TPT), given (daily x 5) x 2, in children with relapsed solid tumors
58. A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent
59. A phase II study of topotecan administered five times daily in patients with advanced gastric cancer
60. Phase II evaluation of topotecan in patients with advanced colorectal cancer
61. A Phase II trial of topotecan (TPT) for the treatment of advanced, measurable colorectal cancer
62. Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials group
63. Phase II trial of topotecan in hepatocellular carcinoma: A Southwest Oncology Group study
64. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease
65. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan
66. Phase II study of topotecan in metastatic non-small-cell lung cancer
67. Randomized Phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung carcinoma (NSCLC): A North Central Cancer Treatment Group (NCCTG) trial
68. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy
69. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
70. Topotecan, and active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
71. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
72. A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer
73. A phase II trial of topotecan for the treatment of relapsed advanced ovarian carcinoma
74. Topotecan, a new active drug, vs. paclitaxel in advanced epithelial ovarian carcinoma: International Topotecan Study Group Trial
75. Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Toptecan Study Group Trial
76. Clinical and laboratory studies of topotecan in breast cancer
77. A phase II study of topotecan on a daily x 5 schedule as second-line single agent therapy in patients with advanced breast cancer
78. Topotecan in the treatment of hematologic malignancies
79. Phase II trial of topotecan in advanced gastric cancer: A Southwest Oncology Group study
80. Phase II trial of topotecan administered as a 72-hour continuous infusion in children with refractory solid tumors: A collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study
81. Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase II study
82. Upfront phase II therapy with taxol (Txl) and topotecan (Topo) in untreated children (>365 days) with disseminated (INSS stage 4) neuroblastoma (NB). A Pediatric Oncology Group (POG) study
83. Topotecan window in patients with rhabdomyosarcoma (RMS): An IRSG study
84. Irinotecan (CPT-11): Pharmacology and clinical applications
85. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996
86. A phase I trial of irinotecan (CPT-11) in children
87. A phase I study of irinotecan in pediatric patients: A Pediatric Oncology Group study
88. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children
89. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion
90. A phase I study of irinotecan (CPT-11) in children with relapsed solid tumors
91. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats
92. CPT-11-induced cholinergic effects in cancer patients
93. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
94. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea
95. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
96. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats
97. An early Phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma
98. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
99. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
100. Current perspectives on camptothecins in cancer treatment
101. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells
102. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
103. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines
104. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line
105. Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro
106. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells
107. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems
108. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro
109. Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence
110. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A cancer and leukemia group B study
111. Phase I trial of cisplatin plus topotecan on a daily x 5 schedule in patients with advanced solid tumors
112. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma
113. A phase I study of carboplatin (C) and escalating dose of topotecan (T) in late recurrent ovarian carcinoma (OVCA)
114. Combination chemotherapy with cisplatin and topotecan as second-line treatment of sensitive (S) and refractory (R) small cell lung cancer (SCLC): An EORTC LCCG phase II study
115. A phase I trial of a fixed systemic exposure (AUC) of carboplatin (CARBO) with continuous infusion (CI) topotecan (TOPO) in pediatric solid tumors
116. Phase I study of continuous infusion (CI) topotecan and carboplatin (CBDCA) for relapsed or refractory acute leukemia (AL)
117. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer
118. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
119. A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer
120. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer
121. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma
122. Phase I study of irinotecan (CPT-11) abd carboplatin (CBDCA) in previously untreated advanced solid cancers
123. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors
124. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
125. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer
126. Phase II study of CPT-11 plus cisplatin in patients with advanced gastric and GE junction carcinomas
127. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer
128. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer
129. Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced nonsmall cell lung cancer (NSCLC)
130. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPY-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase II study
131. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma. A pilot phase II clinical trial and pharmacokinetic profile
132. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
133. Nonproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors
134. Effects of CPT-11 in combination with other anti-cancer agents in culture
135. The significance of the sequence of administration of topotecan and etoposide
136. Topotecan increases topoisomerase II alpha levels and sensitivity to treatment with etoposide in schedule-dependent process
137. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo
138. Experimental studies on biochemical modulation targeting topoisomerase I and II in human atumor xenografts in nude mice
139. A Phase I trial of sequential topotecan and etoposide in adult acute myeloid leukemia (AML)
140. A phase I and pharmacodynamic study of sequential topotecan and etoposide (TE) in adult patients with refractory/relapsed acute leukemia (RAL)
141. Phase I clinical evaluation of timed sequential topotecan followed by mitoxantrone and etoposide in patients with refractory acute leukemia and refractory lymphoma
142. A phase I and pharmacodynamic study of sequential topotecan and etoposide (TE) in adult patients with refractory/relapsed acute leukemia (RAL)
143. Measurement of tumor topoisomerase I and II levels during the sequential administration of topotecan and etoposide
144. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide
145. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide
146. Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
147. A phase I study of sequential doxorubicin and topotecan
148. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer
149. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
150. Phase II study of irinotecan (CPT-11) combined with etoposide (VP-16) for previously untreated extensive-disease small-cell lung cancer (EDSCLC): A study of the West Japan Lung Cancer Group
151. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors
152. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer
153. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia
154. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
155. A phase I/II study of highdose cytarabine and topotecan for the treatment of resistant acute myelogenous leukemia
156. Combination trial of arabinofuranosyl-cytosine 5'-palmitate and topotecan in murine leukemia, L1210
157. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors
158. A phase I and pharmacokinetic (PK) study of CPT-11 (C) and 5-FU (F) combination
159. Weekly irinotecan (CPT-11),leucovorin (LV), and fluorouracil (FU) is superior to daily x 5 LV/FU in patients (PTS) with previously untreated metastatic colorectal cancer (CRC)
160. Combination of irinotecan (CPT-11) and 5-fluorouracil with an analysis of cellular determinants of drug activity
161. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line
162. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo
163. CPT-11 (irinotecan) and 5-fluorouracil: A promising combination for therapy of colorectal cancer
164. A randomized phase III trial comparing irinotecan (IRI) + 5FU/Folinic acid (FA) to the same schedule of 5FU/FA in patients (pts) with metastatic colorectal cancer (MCRC) as front line chemotherapy (CT)
165. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer
166. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A Pediatric Oncology Group study
167. A Phase I and pharmacologic study of a combination of cyclophosphamide and topotecan in patients with refractory acute leukemia and chronic myelogenous leukemia in blast crisis (CML-B)
168. Topotecan and highdose cyclophosphamide: Salvage therapy for pediatric solid tumors
169. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A pediatric oncology group (POG) phase II study
170. The drug pair, topotecan/cyclophosphamide, is active in previously untreated rhabdomyosarcoma (RMS): A report from the intergroup rhabdomyosarcoma study group (IRSG)
171. Irinotecan therapy in adults with recurrent or progressive malignant glioma
172. Topotecan treatment of adults with primary malignant glioma
173. Phase I trial of topotecan plus BCNU in malignant glioma
174. Phase I trial of CPT-11 plus BCNU in malignant glioma
175. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines
176. Topotecan (TPT) inhibits docetaxel (DOC) clearance and increases myelosuppression
177. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study
178. Phase I study of paclitaxel and topotecan in patients with advanced tumors: A cancer and leukemia group B study
179. Phase I study of taxol with 14-day topotecan continuous low-dose infusion
180. Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer
181. Topotecan and paclitaxel, an active couplet, in untreated extensive disease small cell lung cancer
182. Phase II study of paclitaxel plus topotecan with G-CSF support for the treatment of relapsed and refractory aggressive non-Hodgkin's lymphoma
183. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts
184. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
185. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix
186. Late phase II study of CPT-11, a topoisomerase I inhibitor, in advanced cervical carcinoma (CC)
187. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix
188. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
189. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
190. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
191. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer
192. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer
193. A phase II study of a new camptothecin analog CPT-11 in previously treated advanced breast cancer patients
194. A late phase II study of CPT-11 (irinotecan) in advanced breast cancer
195. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer
196. Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC)
197. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC)
198. An early phase II study of CPT-11 in primary lung cancer
199. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer
200. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
201. A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT)